Share on StockTwits
 

Equities researchers at Brean Capital hoisted their price objective on shares of Accuray (NASDAQ:ARAY) from $9.00 to $12.00 in a research report issued on Wednesday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Brean Capital’s price objective points to a potential upside of 30.86% from the stock’s previous close.

A number of other analysts have also recently weighed in on ARAY. Analysts at Sidoti initiated coverage on shares of Accuray in a research note to investors on Thursday, December 19th. They set a “buy” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Accuray in a research note to investors on Monday, December 2nd. They now have a $8.50 price target on the stock. Finally, analysts at Dougherty & Co raised their price target on shares of Accuray from $8.00 to $10.00 in a research note to investors on Monday, November 11th. They now have a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $9.30.

Accuray (NASDAQ:ARAY) opened at 9.17 on Wednesday. Accuray has a one year low of $3.76 and a one year high of $9.38. The stock’s 50-day moving average is $8.64 and its 200-day moving average is $7.3. The company’s market cap is $686.6 million.

Accuray (NASDAQ:ARAY) last announced its earnings results on Thursday, November 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.01. The company had revenue of $76.60 million for the quarter, compared to the consensus estimate of $79.67 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 7.5% on a year-over-year basis. On average, analysts predict that Accuray will post $-0.70 earnings per share for the current fiscal year.

Accuray, Inc manufactures image-guided radiosurgery devices. The Company is based in the United States and its core product, the CyberKnife Stereotactic Radiosurgery System, combines image-guidance with robotics to offer unparalleled flexibility and accuracy.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.